Literature DB >> 9706936

Involvement of nitric oxide in peripheral antinociception mediated by kappa- and delta-opioid receptors.

N Nozaki-Taguchi1, T Yamamoto.   

Abstract

UNLABELLED: Nitric oxide (NO) has been reported to enhance the analgesic effect of the peripherally administered mu-opioid receptor agonists, but the role of NO on the analgesic effect of the peripherally administered kappa and delta opioid receptor agonists is still unclear. We examined the effects of peripherally applied kappa- and delta-opioid receptor agonists and of their interactions with the NO-releasing drug, FK409, on the behavioral response to intraplantar injection of formalin in rats (the formalin test). The formalin injection results in a biphasic appearance of agitation behavior, consisting of the early (Phase 1; 0-9 min) and late (Phase 2; 10-60 min) responses. The active enantiomer of kappa-opioid receptor agonist, (-)U50,488H, dose-dependently suppressed the agitation response in both phases of the formalin test when applied peripherally. A peripheral delta-opioid receptor agonist, [D-Pen(2,5)] enkephalin (DPDPE), suppressed only Phase 2 of the formalin test. Local application of FK409 after the administration of a subthreshold dose of each opioid resulted in a dose-dependent decrease in the Phase 1, but not Phase 2, response to the formalin test for both agonists. Interactions between peripheral opioids and FK409 were reversed with both naloxone and carboxy-PTIO (NO scavenger). Systemic injections of either a kappa- or delta-agonist had no interaction with peripherally applied FK409. Peripheral FK409 alone did not have any significant effect on the formalin test. These data indicate that the antinociceptive effects of peripherally applied kappa- and delta-opioid agonists on the formalin test are potentiated by the local action of NO. IMPLICATIONS: The analgesic effects of peripherally applied kappa- and delta-opioid receptor agonists during inflammation induced by formalin injection in the rat are, at least partly, mediated by the NO-cGMP pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9706936     DOI: 10.1097/00000539-199808000-00028

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

1.  The peripheral administration of a nitric oxide donor potentiates the local antinociceptive effects of a DOR agonist during chronic inflammatory pain in mice.

Authors:  Arnau Hervera; Sergi Leánez; Roger Negrete; Olga Pol
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-07-28       Impact factor: 3.000

2.  Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction.

Authors:  A Ait-Belgnaoui; W Han; F Lamine; H Eutamene; J Fioramonti; L Bueno; V Theodorou
Journal:  Gut       Date:  2006-02-28       Impact factor: 23.059

3.  Antipyretic and antinociceptive effects of Nauclea latifolia root decoction and possible mechanisms of action.

Authors:  Germain Sotoing Taïwe; Elisabeth Ngo Bum; Emmanuel Talla; Théophile Dimo; Norbert Weiss; Neteydji Sidiki; Amadou Dawe; Fleur Clarisse Okomolo Moto; Paul Désiré Dzeufiet; Michel De Waard
Journal:  Pharm Biol       Date:  2010-09-07       Impact factor: 3.503

4.  Opioid Receptor Activity and Analgesic Potency of DPDPE Peptide Analogues Containing a Xylene Bridge.

Authors:  Azzurra Stefanucci; Ettore Novellino; Sako Mirzaie; Giorgia Macedonio; Stefano Pieretti; Paola Minosi; Edina Szűcs; Anna I Erdei; Ferenc Zádor; Sándor Benyhe; Adriano Mollica
Journal:  ACS Med Chem Lett       Date:  2017-03-14       Impact factor: 4.345

Review 5.  Effects of opioids, cannabinoids, and vanilloids on body temperature.

Authors:  Scott M Rawls; Khalid Benamar
Journal:  Front Biosci (Schol Ed)       Date:  2011-06-01

6.  Targeting Nitric Oxide Production in Microglia with Novel Imidazodiazepines for Nonsedative Pain Treatment.

Authors:  Amanda N Nieman; Guanguan Li; Nicolas M Zahn; Md Yeunus Mian; Brandon N Mikulsky; Dylan A Hoffman; Taylor M Wilcox; Alexander S Kehoe; Ian W Luecke; Michael M Poe; David Alvarez-Carbonell; James M Cook; Douglas C Stafford; Leggy A Arnold
Journal:  ACS Chem Neurosci       Date:  2020-06-18       Impact factor: 5.780

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.